Compare Novo Nordisk A/S (NVO) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $57. The key difference: Novo Nordisk A/S pays a 3.63% dividend while SP Funds S&P 500 Sharia Industry Exclusions ETF pays none, and SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | SPUS | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $71.70 | $59.51 |
52-Week Low | $35.29 | $45.32 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
SPUS trades at $56.32, down 0.23% on the day, with a bearish technical outlook from moving averages and oscillators. Key support is at $56, with resistance at $57. The stock's financial ratios, including P/E and P/S, are not available in the provided data. Recent corporate actions include small dividend payments scheduled for mid-2026, indicating a shareholder return focus.
The outlook for SPUS is cautious due to weak technical signals and limited fundamental data visibility. Investment opportunities may lie in its dividend strategy, but risks include market volatility and lack of current financial metrics. Investors should seek updated earnings reports for a clearer fundamental picture before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
